Abstract
The success of conventional chimeric antigen receptor (CAR) therapy in the treatment of refractory hematologic malignancies has triggered the development of novel exciting experimental CAR technologies. Among them, adaptor CAR platforms have received much attention. They combine the flexibility and controllability of recombinant antibodies with the power of CARs. Due to their modular design, adaptor CAR systems propose answers to the central problems of conventional CAR therapy, such as safety and antigen escape. This review provides an overview on the different adaptor CAR platforms available, discusses the possibilities and challenges of adaptor CAR therapy, and summarizes the first clinical experiences.
Highlights
Cancer immunotherapy is a rapidly growing field that is becoming more and more important in clinical practice
We reported that CD98- and EGFR-redirected UniCAR T cells efficiently eliminated radioresistant head and neck cancer cells in vitro and in vivo [63]
These CD16 chimeric antigen receptor (CAR) were combined with the monoclonal antibodies (mAb) rituximab, SEA-B cell maturation antigen (BCMA), and trastuzumab for the treatment of CD20pos
Summary
Cancer immunotherapy is a rapidly growing field that is becoming more and more important in clinical practice. This review will focus on recent advances in the field of switchable adaptor CAR platforms, with emphasis on their safety profile, controllability, target flexibility, and efficiency. CAR of switchable adaptor CAR platforms, with emphasis on their safety profile, controllability, target design has undergone continuous changes from 1st to 4th generation that have improved CAR T cell flexibility, specificity, and efficiency. T cells areconventional able to bind naturally occurring molecules structure adaptor CARs corresponds to the CAR design. TcellTexpansion, specificity and continuous acts as a linker at the interface between the that tumor and the adaptor cell. This cytotoxicity, secretion, and in responses, vivo persistence complex cancytokine mediate anti‐tumor similar[18].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
